Experimental Hematology & Oncology

Article	Citations
Inhibition of EYA family tyrosine phosphatase activity reveals a therapeutic vulnerability and enhances Menin and DOT1L inhibitor efficacy in KMT2A-rearranged leukemia	226
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	180
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity	176
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis	149
A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms	149
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience	113
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside	97
MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting	97
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	90
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	83
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics	79
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling	79
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	78
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux	76
Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy	71
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies	71
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer	69
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers	66
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response	63
Correction: Breast cancer heterogeneity and its implication in personalized precision therapy	62
Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma	61
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma	60
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	59
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone	57
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways	56

Enhanced cellular therapy: revolutionizing adoptive cellular therapy	54
HIV associated lymphoma: latest updates from 2023 ASH annual meeting	51
Role of m6A writers, erasers and readers in cancer	50
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	50
Tetrahydromagnolol targets TRIM38 to mediate PANoptosis in cancer cells and has the potential for synergistic cancer therapy	49
Breast cancer heterogeneity and its implication in personalized precision therapy	48
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies	48
Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting	48
Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways	47
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia	47
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study	45
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma	44
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting	44
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells	43
TCR engineered T cells for solid tumor immunotherapy	43
IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity	42
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma	40
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma	39
Three-dimensional chromatin landscapes in MLLr AML	39
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation	39
Correction: Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	38
Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells	37
The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination	37
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia	35
circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma	34
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes	34
Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bhighCD27low memory-like NK cells	34
Hepatitis B surface antigen: carcinogenesis mechanisms and clinical implications in hepatocellular carcinoma	34
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma	33
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances	33
IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response	32
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs	32
Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis	32
Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study	31
New exploration of KRASG12D inhibitors and the mechanisms of resistance	31
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleuce	31
Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors	30
Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy	30
KMT2A alterations in acute myeloid leukemia: a proposed genetic risk model and transplantation outcomes	29
Disparities in the incidence, mortality and disability-adjusted life years of 33 early-onset cancer groups globally, 2012–2021: a systematic analysis	29
A one-base therapeutic insertion in the HBG2 distal promoter reactivates γ-globin expression	29
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model	29
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation	28
Targeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights	28
Versatile function of NF-ĸB in inflammation and cancer	28
Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review	28
Crosstalk between O-GlcNAcylation and ubiquitination: a novel strategy for overcoming cancer therapeutic resistance	28
Recent advances and future perspectives in the therapeutics of prostate cancer	27
Antibody-drug conjugates in breast cancer: current evidence and future directions	27
Immunotherapy in breast cancer: current landscape and emerging trends	27

Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential	26
The clinical impact of IKZF1 mutation in acute myeloid leukemia	26
Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia	26
Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	26
FGL1-mediated lymph node metastasis in stage T1 non-small cell lung cancer: therapeutic targeting	25
A novel AML1-ETO/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia	25
CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy	25
Downregulation of pro-surfactant protein B contributes to the recurrence of early-stage non-small cell lung cancer by activating PGK1-mediated Akt signaling	25
The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity	24
Antitumor effect of a small-molecule inhibitor of KRASG12D in xenograft models of mucinous appendicular neoplasms	24
Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma	24
Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study	24
Immune-related gene index predicts metastasis for prostate cancer patients undergoing radical radiotherapy	24
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma	23
Validation of a microRNA profile in urine liquid biopsy with diagnostic and stratification value for bladder cancer classification, available through the open app BladdermiRaCan	23
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting	23
CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications	23
Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer	23
The roles of tissue resident macrophages in health and cancer	22
Immunotherapy in chronic lymphocytic leukemia: advances and challenges	22
Incidence, mortality, and risk factors of bladder, kidney, prostate and testicular cancers in China and comparisons with the United States, the United Kingdom, Japan, and the Republic of Korea: an up-	22
Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis	22
Efficacy of melflufen in multiple myeloma with mutated or deleted TP53	22
Sarcosine sensitizes lung adenocarcinoma to chemotherapy by dual activation of ferroptosis via PDK4/PDHA1 signaling and NMDAR-mediated iron export	22
The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment	22
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy	22
DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia	22
Bladder cancer subtypes exhibit limited plasticity across different microenvironments and in metastases	21
Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients	21
Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA	21
Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting	21
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma	21
Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults	21
Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	21
Resolving intra-tumor heterogeneity and clonal evolution of core-binding factor acute myeloid leukemia patients with single-cell resolution	21
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities	20
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma	20
Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance	20
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies	19
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies	19
An ureido-substituted benzenesulfonamide carbonic anhydrase inhibitor exerts a potent antitumor effect in vitro and in vivo	19
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA	19
Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancer	19
Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates	18
HOXA13 promotes gastric cancer progression partially via the FN1-mediated FAK/Src axis	18
In-depth insight into tumor-infiltrating stromal cells linked to tertiary lymphoid structures and their prospective function in cancer immunotherapy	18
Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies	18
Global burden and trends of hematologic malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021	17
Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trial	17
Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications	17
Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer	17
Anti-tumor vaccine efficacy depends on adjuvant type and associates with induced IgG subclass and glycosylation profiles	17
Improving CAR-T cell function through a targeted cytokine delivery system utilizing car target-modified extracellular vesicles	17
Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting	17
Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer	16
Revealing the role of the gut microbiota in enhancing targeted therapy efficacy for lung adenocarcinoma	16
TLR7/8 signaling activation enhances the potency of human pluripotent stem cell-derived eosinophils in cancer immunotherapy for solid tumors	16
Outcomes of allogeneic hematopoietic stem cell transplantation in R/R DLBCL patients with failure of CAR-T therapy	16
YAP-induced MAML1 cooperates with STAT3 to drive hepatocellular carcinoma progression	16
CDCA8 induced by NF-YA promotes hepatocellular carcinoma progression by regulating the MEK/ERK pathway	15
ZMIZ2 facilitates hepatocellular carcinoma progression via LEF1 mediated activation of Wnt/β-catenin pathway	15
A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma	15
The lncRNA PARylator promotes PARP1 activation and resistance to DNA‑damaging therapy in esophageal squamous cell carcinoma	15
Cirrhotic-extracellular matrix attenuates aPD-1 treatment response by initiating immunosuppressive neutrophil extracellular traps formation in hepatocellular carcinoma	15
CUL4B-DDB1-COP1-mediated UTX downregulation promotes colorectal cancer progression	15
The role of organoids in cancer research	15
Role of CDK4 as prognostic biomarker in Soft Tissue Sarcoma and synergistic effect of its inhibition in dedifferentiated liposarcoma sequential treatment	15
CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy	15
MMP14 from BM-MSCs facilitates progression and Ara-C resistance in acute myeloid leukemia via the JAK/STAT pathway	14
AOH1996 targets mitochondrial dynamics and metabolism in leukemic stem cells via mitochondrial PCNA inhibition	14
RNA binding proteins in MLL-rearranged leukemia	14
Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence	14
A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer	14
Identification of adenoid subtype characterized with immune-escaped phenotype in lung squamous carcinoma based on transcriptomics	14
Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases	14
Comparison of local ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: a	14
The genomic analysis brings a new piece to the molecular jigsaw of idiopathic erythrocytosis	14
Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting	14
Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study	14
The role of neutrophil extracellular traps in cancer progression, metastasis and therapy	14

Elevated expression of the RNA-binding protein IGF2BP1 enhances the mRNA stability of INHBA to promote the invasion and migration of esophageal squamous cancer cells	14
Reconstructed colorectal cancer model to dissect the anti-tumor effect of mesenchymal stromal cells derived extracellular vesicles	13
Chimeric antigen receptor modified hematopoietic stem cells (CAR-HSCs) arm all immune forces for anti-tumor in mice	13
A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease	13
ProNGF promotes brain metastasis through TrkA/EphA2 induced Src activation in triple negative breast cancer cells	13
Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects	13
Trends in platelet count among cancer patients	13
Spatial ecostructural modelling of endometrial cancer identifies the key role of CD90 + CD105 + endothelial cells in tumour heterogeneity and predicts disease recurrence	13
Heterogeneity of the tumor immune microenvironment and its clinical relevance	13
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers	13
RHO GTPase family in hepatocellular carcinoma	13
EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies	13
Ubiquitin modification in the regulation of tumor immunotherapy resistance mechanisms and potential therapeutic targets	13
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era	13
Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer	13
Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell lymphoma	13
TRIM family contribute to tumorigenesis, cancer development, and drug resistance	13
Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines	13
Secretogranin II influences the assembly and function of MHC class I in melanoma	12
Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer	12
Analysis of CD20 and PD-L1 levels on small extracellular vesicles (sEV) produced by DLBCL cells and EBV-transformed B cells, and potential role in T cell inhibition	12
Transfer RNA-derived small RNA: an emerging small non-coding RNA with key roles in cancer	12
Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting	12
Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials	12
ANXA6/TRPV2 axis promotes lymphatic metastasis in head and neck squamous cell carcinoma by inducing autophagy	12
Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells	12
Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer	11
LINP1 represses unfolded protein response by directly inhibiting eIF2α phosphorylation to promote cutaneous squamous cell carcinoma	11
Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy	11
Unravelling neutropenic enterocolitis: insights from gut microbiota, and intestinal barrier analyses	11
Multi-omics analyses of the heterogenous immune microenvironment in triple-negative breast cancer implicate UQCRFS1 potentiates tumor progression	11
Vertical targeting of the PI3K/AKT pathway at multiple points is synergistic and effective for non-Hodgkin lymphoma	11
Platelets in cancer and immunotherapy: functional dynamics and therapeutic opportunities	11
Radiation-induced exosomal miR-21 enhances tumor proliferation and invasiveness in breast cancer: implications for poor prognosis in radiotherapy patients	11
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors	11
The gut microbiota as a booster for radiotherapy: novel insights into radio-protection and radiation injury	11
METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression	11
Current insight into the regulation of PD-L1 in cancer	11
Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition	11
Application patterns and outcomes of hematopoietic stem cell transplantation in peripheral T-cell lymphoma patients: a multicenter real-world study in China	11
A Pig-a conditional knock-out mice model mediated by Vav-iCre: stable GPI-deficient and mild hemolysis	11
CAR-T cell combination therapies in hematologic malignancies	11
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect	11
GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment	11
Identification of a novel NPM1 mutation in acute myeloid leukemia	11
Recent advances and challenges of cellular immunotherapies in lung cancer treatment	11
Molecular profiling of skin cells identifies distinct cellular signatures in radiation-induced skin injury across various stages in the murine dataset	11
VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses	11
Thioredoxin-1 regulates self-renewal and differentiation of murine hematopoietic stem cells through p53 tumor suppressor	10
Distinct response to IL-1β blockade in liver- and lung-specific metastasis mouse models of pancreatic cancer with heterogeneous tumor microenvironments	10
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment	10
Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers	10
p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma	10
Targeting collagen to optimize cancer immunotherapy	10
Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer	10
The clinical landscape of CAR NK cells	10
Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting	10
Genetic factors, risk prediction and AI application of thrombotic diseases	10
Exploring coding and signal joints of novel TCR beta D-D rearrangements for tracking T-cell leukemia clonality	10
Targeting NOTCH1 in combination with antimetabolite drugs prolongs life span in relapsed pediatric and adult T-acute lymphoblastic leukemia xenografts	10
Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer	10
Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells	10
Current and future therapies for follicular lymphoma	10
Bisecting GlcNAc enhances CD8+ T cell-mediated killing of breast cancer by suppressing PD-L1 expression and its binding to PD-1	10
Targeting metabolic reprogramming in chronic lymphocytic leukemia	9
Targeting CD22 for B-cell hematologic malignancies	9
Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment	9
Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients post-Allo-HSCT: a phase I trial	9
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting	9
Natural killer cell-based cancer immunotherapy: from basics to clinical trials	9
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia	9
Developments in nanotechnology approaches for the treatment of solid tumors	9
Epigenetic alterations of TP53INP1 by EHMT2 regulate the cell cycle in gastric cancer	9
Bone marrow sympathetic neuropathy is a hallmark of hematopoietic malignancies and it involves severe ultrastructural damage	9
Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion	9
New insight into circRNAs: characterization, strategies, and biomedical applications	9
Increasing cure rates of solid tumors by immune checkpoint inhibitors	9
CD47 antibody-armed oncolytic adenovirus promotes chimeric antigen receptor macrophage phagocytosis and antitumor immunity	9
The GPIb-IX complex on platelets: insight into its novel physiological functions affecting immune surveillance, hepatic thrombopoietin generation, platelet clearance and its relevance for cancer devel	8
CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro	8
Advances and challenges in the treatment of myelodysplastic syndromes	8
Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer	8
New approaches to idiopathic neutropenia in the era of clonal hematopoiesis	8
Age-related accumulation of B-1 cell progenitors in mice reflects changes in miR15a/16-1 expression and radioresistance capacity	8
Targeting platelet-tumor cell interactions via thromboxane A2-prostanoid receptor blockade to reduce metastasis in triple negative breast cancer	8
Extracellular matrix stiffness reduces DNA 6 ma level to facilitate colorectal cancer progression via disrupting P53 binding to CDKN1A promoter	8
Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside	8
CD105+CAF-derived exosomes CircAMPK1 promotes pancreatic cancer progression by activating autophagy	8
Sphingosine kinase 1 contributes to the metastatic potential of epithelial ovarian cancer to the adipocyte-rich niche	8
Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting	8
Metastatic clear-cell renal cell carcinoma: a frequent NOTCH1 mutation predictive of response to anti-NOTCH1 CB-103 treatment	8
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsul	8
Deciphering tumor-infiltrating dendritic cells in the single-cell era	8